91 results
8-K
EX-99.1
IXHL
Incannex Healthcare Limited
30 Sep 24
Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates
4:01pm
for the treatment of patients with obstructive sleep apnea (OSA). RePOSA, a randomized, double-blind trial, is designed to assess the safety and efficacy … 2b clinical trial of PSX-001 evaluating change in the HAM-A anxiety score, and other measures of efficacy and safety at sites in the U.S. and UK
10-K
2024 FY
IXHL
Incannex Healthcare Limited
30 Sep 24
Annual report
7:30am
. The ongoing Phase 2/3 clinical trial further investigates the safety and efficacy of IHL-42X for the treatment of OSA. The Phase 2 portion is being … and safety study in 2024.
PSX-001, our drug candidate in Phase 2b clinical development, is an oral synthetic psilocybin treatment, administered
8-K
EX-10.2
IXHL
Incannex Healthcare Limited
10 Sep 24
Entry into a Material Definitive Agreement
7:30am
relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each
8-K
EX-99.1
IXHL
Incannex Healthcare Limited
5 Aug 24
FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed
8:15am
following review of IND dossier containing information on the clinical trial, as well as safety and quality of the investigational drug product … , healthcare utilisation, electroencephalography (EEG), as well as assessment of safety and tolerability through adverse event monitoring.
Incannex
8-K
EX-99.1
IXHL
Incannex Healthcare Limited
30 Jul 24
Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X
9:00am
pharmacokinetic profiles will facilitate the Company’s ability to rely on safety and toxicology data for the reference listed drugs in future regulatory … submissions. The adverse event data from the BA/BE study will also contribute to the safety profile of IHL-42X as a combination product.
Incannex Chief
S-1/A
8q8cbv5m 8haojhjuj
17 Jul 24
IPO registration (amended)
8:47am
S-1/A
EX-10.9
yp9 38cjl2
17 Jul 24
IPO registration (amended)
8:47am
S-1
vekuk5d
3 Jul 24
IPO registration
6:29am
8-K
EX-99.1
8n00szw h61c
30 May 24
Other Events
8:30am
8-K
EX-99.1
c48y8svr8 1s71jaqlw
7 May 24
Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder
8:30am
8-K
EX-99.1
x8sm jz527vmou3
16 Apr 24
Incannex Healthcare Inc. Quarterly Update, Q1 2024
9:30am
8-K
EX-10.1
fbce00r
5 Mar 24
Departure of Directors or Certain Officers
6:11am
8-K
EX-99.1
i1wyiov5wwt6
28 Feb 24
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder
7:42am
8-K
EX-99.1
d9p yqh39gyp21s
16 Feb 24
Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation
8:00am
10-Q
luf8uf0k
14 Feb 24
Quarterly report
6:16am
10-Q
EX-10.14
u0xe ph8davr89
14 Feb 24
Quarterly report
6:16am
8-K
EX-99.1
0uzgo
1 Feb 24
Other Events
7:30am
8-K
EX-99.1
metd0zmb0ndq83lh0own
24 Jan 24
Other Events
4:30pm
8-K
axyozs osspwi4367d
24 Jan 24
Other Events
4:30pm